Get the Stockscreener App
2.665
0.76%
0.035
Anixa Biosciences Inc stock is traded at $2.665, with a volume of 32,957.
It is up +0.76% in the last 24 hours and down -14.52% over the past month.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
See More
Previous Close:
$2.63
Open:
$2.59
24h Volume:
32,957
Relative Volume:
0.30
Market Cap:
$85.64M
Revenue:
-
Net Income/Loss:
$-10.74M
P/E Ratio:
-7.8382
EPS:
-0.34
Net Cash Flow:
$-6.53M
1W Performance:
-8.30%
1M Performance:
-14.52%
6M Performance:
-14.24%
1Y Performance:
-17.96%
1-Day Range:
$2.58
$2.83
1-Week Range:
$2.58
$3.01
52-Week Range:
$2.07
$4.20
Anixa Biosciences Inc Stock (ANIX) Company Profile
Name
Anixa Biosciences Inc
Sector
Industry
Phone
408-708-9808
Address
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
Compare ANIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIX
Anixa Biosciences Inc
|
2.695 | 85.64M | 0 | -10.74M | -6.53M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.58 | 124.73B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
717.57 | 78.72B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
571.84 | 34.70B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
238.81 | 30.20B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
244.60 | 26.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-23-22 | Initiated | Chardan Capital Markets | Buy |
| Apr-12-21 | Initiated | H.C. Wainwright | Buy |
Anixa Biosciences Inc Stock (ANIX) Latest News
Anixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties - BioSpace
Anixa Biosciences (ANIX) to Release Earnings on Tuesday - Defense World
Anixa Biosciences to Present at the 18th Annual European Life Sc - GuruFocus.com
Anixa Biosciences : to Hold Conference Call to Discuss Outlook for 2019 -January 16, 2019 at 07:31 am EST - Marketscreener.com
Anixa Biosciences Announces Chief Development Officer Dr. Pam Garzone to Speak at the Alliance for Cancer Gene Therapy Summit 2025 on March 19th - PR Newswire
Spotlight On February 2025's Promising Penny Stocks - Yahoo Finance
Anixa Biosciences and Moffitt Cancer Center Complete Dosing in Third Cohort in Ovarian Cancer CAR-T Clinical Trial - PR Newswire
Can Anixa's Ovarian Cancer CAR-T Therapy Advance After Successful 10-Fold Dose Escalation? - StockTitan
Anixa Biosciences' Breast Cancer Vaccine was Featured on Fox New - GuruFocus.com
Can This Breast Cancer Vaccine Change Prevention Forever? Anixa's Trial Shows 70% Response Rate - StockTitan
Anixa Biosciences Featured in Breaking Cancer News Article on No - GuruFocus.com
Anixa Biosciences Featured in Breaking Cancer News Article on Novel CAR-T Therapy for Ovarian Cancer - PR Newswire
HC Wainwright Issues Optimistic Forecast for ANIX Earnings - Defense World
Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
HC Wainwright Reaffirms “Buy” Rating for Anixa Biosciences (NASDAQ:ANIX) - Armenian Reporter
Anixa Biosciences’ (ANIX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Anixa Biosciences Announces Approval of Protocol Amendment for O - GuruFocus.com
Anixa Biosciences expands CAR-T therapy trial for ovarian cancer - Investing.com
Anixa Biosciences expands CAR-T therapy trial for ovarian cancer By Investing.com - Investing.com South Africa
Anixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical Trial - PR Newswire
Major Breakthrough: Anixa's Ovarian Cancer Trial ExpandsSecond CAR-T Dose Now Available for Patients - StockTitan
Anixa Biosciences director Lewis Titterton buys $6,020 worth of stock - MSN
Anixa Biosciences director Lewis H. Titterton Jr. buys $15,540 in stock - MSN
Short Interest in Anixa Biosciences, Inc. (NASDAQ:ANIX) Expands By 13.7% - MarketBeat
Revolutionary Cancer Treatment Alert: Anixa's Dual-Attack Strategy Against Ovarian and Breast Cancer Unveiled - StockTitan
Anixa Biosciences Chairman and CEO Discusses Pioneering CAR-T Cell Therapy and Breast Cancer Vaccine in Alpha Wolf Trading Interview - PR Newswire
Anixa Biosciences to Present at the 18th Annual European Life Sciences CEO Forum - sharewise
Anixa Biosciences Inc (ANIX) Stock: A Closer Look at the Market Potential - The News Heater
Contrasting Eterna Therapeutics (NASDAQ:ERNA) and Anixa Biosciences (NASDAQ:ANIX) - Defense World
Breakthrough Cancer Prevention: Anixa CEO Reveals Novel Vaccine Strategy Against Triple-Negative Breast Cancer - StockTitan
Anixa Biosciences' Chairman & CEO Dr. Amit Kumar Featured on CW39's H-Town Live to Discuss the Future of Breast Cancer Prevention - PR Newswire
Insider Buying: Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Purchases 5,000 Shares of Stock - MarketBeat
Anixa biosciences director Arnold Baskies buys $14,100 in stock - MSN
Insider Buying: Arnold Baskies Acquires Additional Shares of Ani - GuruFocus.com
Anixa biosciences director Arnold Baskies buys $14,100 in stock By Investing.com - Investing.com UK
Anixa Biosciences director Titterton buys $8,820 in common stock - MSN
Anixa Biosciences director Titterton buys $8,820 in common stock By Investing.com - Investing.com Australia
Anixa Biosciences’ (ANIX) Buy Rating Reiterated at D. Boral Capital - Defense World
Anixa Biosciences reports progress in cancer vaccine trials - MSN
Anixa Biosciences director Lewis Titterton buys $6,020 worth of stock By Investing.com - Investing.com Australia
Insider Buying: Titterton Lewis H jr Acquires Additional Shares of Anixa Biosciences Inc (ANIX) - GuruFocus.com
Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Purchases $15,540.00 in Stock - MarketBeat
Anixa Biosciences Inc Stock (ANIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.89%
1.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):